117 related articles for article (PubMed ID: 2541044)
21. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
22. The potentiating effect of KC-404 on prostacyclin-induced vasodilation in isolated human cerebral artery.
Onoue H; Kaito N; Tokudome S; Irikura T; Okada K; Abe T; Nakamura N
Gen Pharmacol; 1992 Nov; 23(6):1093-5. PubMed ID: 1487119
[TBL] [Abstract][Full Text] [Related]
23. The effect of low-density lipoproteins on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets.
Bruckdorfer KR; Buckley S; Hassall DG
Biochem J; 1984 Oct; 223(1):189-96. PubMed ID: 6093767
[TBL] [Abstract][Full Text] [Related]
24. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
Manrique RV; Manrique V
Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
[TBL] [Abstract][Full Text] [Related]
25. Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation.
Buttrick PM; Forscher CA; Sussman II; Mueller HS
Am Heart J; 1985 Jun; 109(6):1258-63. PubMed ID: 2988323
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Iloprost, Cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets.
Ashby B
Prostaglandins; 1992 Mar; 43(3):255-61. PubMed ID: 1378640
[TBL] [Abstract][Full Text] [Related]
27. Effects of inhalational anesthetics on alpha2-adrenergic signaling in isolated platelets.
Pentyala S; Moller D; Chowdhury A; Sung KY; Rebecchi M
Toxicol Lett; 1998 Nov; 100-101():115-20. PubMed ID: 10049130
[TBL] [Abstract][Full Text] [Related]
28. Exhibition of anti-platelet effect of isocarbacyclin methyl ester and its free acid via an increase in cAMP in platelets.
Aoki Y; Inoue K; Kitahara S; Kiyoki M; Araki H
Arzneimittelforschung; 1995 Sep; 45(9):970-4. PubMed ID: 7488315
[TBL] [Abstract][Full Text] [Related]
29. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
Bowen R; Haslam RJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
[TBL] [Abstract][Full Text] [Related]
30. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).
Cox CP; Linden J; Said SI
Peptides; 1984; 5(2):325-8. PubMed ID: 6206481
[TBL] [Abstract][Full Text] [Related]
31. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
Alheid U; Reichwehr I; Förstermann U
Eur J Pharmacol; 1989 May; 164(1):103-10. PubMed ID: 2546782
[TBL] [Abstract][Full Text] [Related]
32. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
34. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats.
Umetsu T; Murata T; Nishio S
Arzneimittelforschung; 1989 Jan; 39(1):68-73. PubMed ID: 2541730
[TBL] [Abstract][Full Text] [Related]
35. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
36. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
37. Mastoparan promotes exocytosis and increases intracellular cyclic AMP in human platelets. Evidence for the existence of a Ge-like mechanism of secretion.
Wheeler-Jones CP; Saermark T; Kakkar VV; Authi KS
Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):465-72. PubMed ID: 1310599
[TBL] [Abstract][Full Text] [Related]
38. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition.
Siess W; Lapetina EG
Biochem J; 1990 Nov; 271(3):815-9. PubMed ID: 1700902
[TBL] [Abstract][Full Text] [Related]
39. Forskolin alters sensitivity of the cAMP-generating system to stimulatory as well as to inhibitory agonists. A study with intact human platelets and guinea pig myometrium.
Mokhtari A; Do Khac L; Harbon S
Eur J Biochem; 1988 Sep; 176(1):131-7. PubMed ID: 2843365
[TBL] [Abstract][Full Text] [Related]
40. Effects of protopine on blood platelet aggregation. II. Effect on metabolic system of adenosine 3',5'-cyclic monophosphate in platelets.
Shiomoto H; Matsuda H; Kubo M
Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2320-2. PubMed ID: 2177684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
